Albert Lowe
Stock Analyst at Craig-Hallum
(0.65)
# 3,834
Out of 4,843 analysts
7
Total ratings
42.86%
Success rate
-14.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Buy | $6 | $0.99 | +503.32% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $1.98 | +607.07% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $1.87 | +488.24% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $3.41 | +134.60% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $0.66 | +501.78% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $0.88 | +583.22% | 1 | May 13, 2024 |
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $0.99
Upside: +503.32%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $1.98
Upside: +607.07%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $1.87
Upside: +488.24%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $3.41
Upside: +134.60%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $0.66
Upside: +501.78%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.88
Upside: +583.22%